Novartis Is Going Before The FDA — But Kite Could Benefit More – Investor’s Business Daily
Investor’s Business Daily |
Novartis Is Going Before The FDA — But Kite Could Benefit More
Investor’s Business Daily CAR–T therapies involve removing immune cells from a patient's blood and then programming them to seek out and destroy cancer cells. But some of these therapies have proven toxic to the nervous system. Meanwhile, the lag in turnaround time remains a … |
